NY-TERRAFORMATION
Terraformation, a global reforestation company, has launched the Seed to Carbon Forest Accelerator, the world’s first biodiversity-focused, carbon-funded forest accelerator program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221031005421/en/
Photo: The Kilimanjaro Project (Photo: Business Wire)
In the next decade, the world will need thousands of new reforestation teams to capture carbon at scale and limit the impacts of climate change. The new forest accelerator will help meet this need by providing forestry teams with the tools to launch restoration projects and succeed at scale. These include early-stage financing, training in resilient native ecosystem restoration, and tools to increase project transparency in critical early stages.
This wraparound platform to launch emerging forestry teams is unique in the industry and brings much-needed support to expand the supply of forest carbon.
The carbon buyers and companies who provide early financing to accelerator cohorts lock in access to the premium-quality carbon credits the projects generate. By providing this financing, buyers secure access to a portfolio of verified carbon credits from geographically diverse projects selected by the company’s carbon science team. Terraformation is looking to connect with finance partners to launch a new accelerator cohort early next year.
The accelerator program is a direct response to the largest bottlenecks to mass-scale restoration: in a recent Terraformation survey of 230 forestry organizations around the globe, 95% of respondents said funding was their biggest concern.[1]
The accelerator builds on Terraformation’s successful pilot restoration projects. Since the company began its global programs in 2020, it has successfully launched 16 restoration projects across 11 countries and created more than 400 new sustainable jobs.
Yishan Wong, founder and CEO of Terraformation, said: “The planet needs to rapidly scale reforestation efforts to address the climate crisis. And more investors than ever are looking for opportunities in carbon capture. But there hasn’t been a clear vehicle providing those investors access to high-quality carbon credits. At the same time, communities around the world are launching vital restoration efforts, but lack the funding, training and technology they need to scale.
“Our accelerator will rapidly expand the number of high-quality forest restoration projects and increase the planet’s capacity for carbon capture.”
María José Iturralde, co-founder of Humans for Abundance, a Terraformation restoration partner, said: “Funding can turn land management around by supporting new sustainable business models that replace deforestation for profit. Startup capital creates opportunities for training, education and infrastructure that allows communities to sustainably restore ecosystems and commercialize their new products in a new way.”
Apply to the accelerator
Applying to and participating in the Seed to Carbon Forest Accelerator is free and open to all forestry teams that prioritize biodiversity and benefits to local communities. Interested organizations and forestry teams are invited to apply to the accelerator beforeNovember 27, 2022. Read more and apply here.
Selected teams will receive a feasibility study to assess carbon project viability on their land, as well as access to expert training in seed collection and banking, biodiverse forest restoration, sustainable business models, marketing and finance. Teams will also receive access to carbon buyers, as well as to new, state-of-the-art project tracking software to streamline monitoring, reporting and verification of project progress, and more. Terraformation will encourage forestry teams to promote women’s leadership, offer community education and create sustainable, local economic impact.
Forestry teams selected to participate in the first cohort will be announced in early 2023.
Fund new forest carbon projects
Carbon buyers and companies interested in funding accelerator forest projects and accessing premium-quality, biodiverse, verified carbon credits can learn more here.
*ENDS*
NOTE TO EDITORS:
About Terraformation
Terraformation is dedicated to restoring the world’s forests to stabilize our climate, revive ecosystems, and build thriving communities.
The company hosts a forest carbon accelerator, supporting early-stage forestry teams to launch, build, and scale biodiverse reforestation projects. In addition to producing high-quality, verified carbon credits, these projects generate complementary sustainable revenue streams to support local economies.
Terraformation’s current partner network spans five continents and includes diverse landowners and organizations. It was founded in 2019 by Yishan Wong, former CEO of Reddit.
Footnotes
[1] Terraformation research conducted in summer 2022 with a survey of 230 respondents from 63 countries. Interviews were also completed with 70 respondents from 29 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221031005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
